{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:54:20Z","timestamp":1792457660692,"version":"4.5.0"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring (TDM) is essential for controlling pharmacogenetic and pharmacokinetic variations and for optimizing pharmacotherapy. However, its value is often underestimated because of nonsystematic recommendations for target ranges in the literature. The purpose of this study was to emphasize transparency and systematization in the forthcoming Updates to the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-TDM Consensus Guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Here, a stepwise method for determining therapeutic reference ranges (TRRs) in psychiatry is introduced. By using various data types, a multidimensional approach for establishing a range is presented. The data types were classified based on how effectively they supported the target ranges. This method was demonstrated for 3 drugs commonly used in psychiatry (aripiprazole, olanzapine, and escitalopram).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Despite the methodological shortcomings in published concentration-effect studies, the approach used here enabled the determination of reference ranges by combining multiple types of data. The lower limit of the TRR is ideally derived from studies that link blood drug concentrations to clinical effectiveness, particularly symptom-specific responses, after fixed-dose treatment. The upper limit depends on the concentrations associated with adverse reactions or maximal response. Thresholds can be estimated using receiver operating characteristic analyses. Preliminary thresholds were derived from responder concentration data or from expected drug concentrations under approved doses. Positron emission tomography studies were used to further validate these ranges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study proposed a new standard for determining the TRR of psychotropic drugs, thereby enhancing their clinical utility and validity. Adjusting blood levels to these ranges should improve response rates and medication tolerance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001264","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T15:00:30Z","timestamp":1739545230000},"page":"199-210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP"],"prefix":"10.1097","volume":"47","author":[{"given":"Xenia M.","family":"Hart","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan;"},{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany;"},{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Amann","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany;"},{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Clinic of Psychiatry and Psychotherapy, University Medicine G\u00f6ttingen (UMG), G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Z\u00fcrich, Z\u00fcrich, Switzerland;"},{"name":"The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York;"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Steimer","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany;"},{"name":"DGKL, Sektion Therapeutisches Drug Monitoring und Klinische Toxikologie;"},{"name":"INSTAND e.V., Gesellschaft Zur F\u00f6rderung der Qualit\u00e4tssicherung in Medizinischen Laboratorien e.V;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Zernig","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Experimental Psychiatry Unit, Department of Psychiatry, Medical University of Innsbruck, Innsbruck, Austria;"},{"name":"Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany;"},{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Working Group \u201cTherapeutic Drug Monitoring\u201d;"},{"name":"Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany; and"},{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1365-2125.2012.04237.x","article-title":"An agenda for UK clinical pharmacology: monitoring drug therapy","volume":"73","author":"Buclin","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12874-017-0363-z","article-title":"Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice","volume":"17","author":"Cooney","year":"2017","journal-title":"BMC Med Res Methodol."},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0043-117891","article-title":"A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology","volume":"51","author":"de Leon","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002130050260","article-title":"Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients","volume":"131","author":"Deuschle","year":"1997","journal-title":"Psychopharmacology"},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00101-007-1191-z","article-title":"Intoxication with a tricyclic antidepressant","volume":"56","author":"Sakka","year":"2007","journal-title":"Der Anaesthesist"},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-002-0448-3","article-title":"Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach","volume":"58","author":"Meyer-Barner","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00004714-200108000-00011","article-title":"Doxepin plasma concentrations: is there really a therapeutic range?","volume":"21","author":"Leucht","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/15622975.2021.1878427","article-title":"Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants","volume":"22","author":"Eap","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","article-title":"Therapeutic Drug Monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don't work","volume":"20","author":"Preskorn","year":"2014","journal-title":"J Psychiatr Pract"},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archpsyc.62.9.961","article-title":"Control group bias in randomized atypical antipsychotic medication trials for schizophrenia","volume":"62","author":"Woods","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.npp.1300059","article-title":"Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports","volume":"28","author":"Khan","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"826138","DOI":"10.3389\/fpsyt.2022.826138","article-title":"Is therapeutic drug monitoring relevant for antidepressant drug therapy? Implications from a systematic review and meta-analysis with focus on moderating factors","volume":"13","author":"Funk","year":"2022","journal-title":"Front Psychiatry"},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pnpbp.2019.01.001","article-title":"Duloxetine plasma level and antidepressant response","volume":"92","author":"De Donatis","year":"2019","journal-title":"Prog Neuropsychopharmacol Bio.l Psychiatry"},{"key":"R18-20250314","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.3.5770.331","article-title":"Relationship between plasma level and therapeutic effect of nortriptyline","volume":"3","author":"Asberg","year":"1971","journal-title":"Br Med J."},{"key":"R19-20250314","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881109104849","article-title":"Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients","volume":"24","author":"Yasui-Furukori","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R20-20250314","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00004714-199712000-00006","article-title":"Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients","volume":"17","author":"Perry","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R21-20250314","doi-asserted-by":"crossref","first-page":"787043","DOI":"10.3389\/fpsyt.2021.787043","article-title":"Therapeutic reference ranges for psychotropic drugs: a protocol for systematic reviews","volume":"12","author":"Hart","year":"2021","journal-title":"Front Psychiatry"},{"key":"R22-20250314","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/15622975.2018.1557346","article-title":"WFSBP guidelines on how to grade treatment evidence for clinical guideline development","volume":"20","author":"Hasan","year":"2019","journal-title":"World J Biol Psychiatry"},{"key":"R23-20250314","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00213-022-06233-2","article-title":"Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis","volume":"239","author":"Hart","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"R24-20250314","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-023-06484-7","article-title":"Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis","volume":"241","author":"Lense","year":"2024","journal-title":"Psychopharmacology"},{"key":"R25-20250314","doi-asserted-by":"crossref","first-page":"972141","DOI":"10.3389\/fpsyt.2022.972141","article-title":"Systematic review and meta-analysis on the therapeutic reference range for escitalopram: blood concentrations, clinical effects and serotonin transporter occupancy","volume":"13","author":"Eichentopf","year":"2022","journal-title":"Front Psychiatry"},{"key":"R26-20250314","first-page":"24","article-title":"The therapeutic reference range for olanzapine revised \u2013 how to combine old and new findings","volume":"55","author":"Wesner","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"R27-20250314","doi-asserted-by":"crossref","first-page":"104077","DOI":"10.1016\/j.nsa.2024.104077","article-title":"Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis","volume":"3","author":"Amann","year":"2024","journal-title":"Neurosci Appl"},{"key":"R29-20250314","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00003088-200241110-00004","article-title":"Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression","volume":"41","author":"Ulrich","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R30-20250314","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/FTD.0000000000000036","article-title":"Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders","volume":"36","author":"Tomita","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R31-20250314","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/15622975.2021.1938668","article-title":"Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients","volume":"23","author":"De Donatis","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"R32-20250314","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-2039-2829","article-title":"Low escitalopram concentrations in patients with depression predict treatment failure: a naturalistic retrospective study","volume":"56","author":"Hart","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"R33-20250314","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0031-1286282","article-title":"Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging","volume":"44","author":"Gr\u00fcnder","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R34-20250314","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R35-20250314","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0000000000000962","article-title":"Dose-related reference range as a tool in therapeutic drug monitoring","volume":"44","author":"Haen","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R36-20250314","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00007691-200312000-00006","article-title":"Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia","volume":"25","author":"Fellows","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R37-20250314","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2009.32","article-title":"Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome","volume":"10","author":"Laika","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"R38-20250314","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00228-018-2419-3","article-title":"Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine","volume":"74","author":"Korell","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R39-20250314","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00406-022-01491-9","article-title":"Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder","volume":"273","author":"Hart","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"R28-20250314","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","article-title":"How important are gender differences in pharmacokinetics?","volume":"41","author":"Meibohm","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R40-20250314","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/17425255.4.4.413","article-title":"Sex-specific differences in CYP450 isoforms in humans","volume":"4","author":"Scandlyn","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R41-20250314","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol Rev"},{"key":"R42-20250314","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"R43-20250314","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jpsychires.2005.10.003","article-title":"Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia","volume":"41","author":"M\u00fcller","year":"2007","journal-title":"J Psychiatr Res"},{"key":"R44-20250314","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R45-20250314","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-200404000-00010","article-title":"Therapeutic drug monitoring of psychotropic drugs. TDM \u201cnouveau\u201d","volume":"26","author":"Bengtsson","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R46-20250314","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00406-016-0736-z","article-title":"Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns","volume":"267","author":"Paulzen","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"R47-20250314","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00406-019-01005-0","article-title":"Pharmacokinetic correlates of venlafaxine: associated adverse reactions","volume":"269","author":"Schoretsanitis","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"R48-20250314","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1023\/A:1011907920641","article-title":"Modeling of pharmacokinetic\/pharmacodynamic (PK\/PD) relationships: concepts and perspectives","volume":"16","author":"Derendorf","year":"1999","journal-title":"Pharm Res."},{"key":"R49-20250314","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2007-979327","article-title":"Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial","volume":"31","author":"H\u00e4rtter","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"R50-20250314","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000088","article-title":"Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder","volume":"36","author":"Kagawa","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R51-20250314","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/JCP.0b013e3182356255","article-title":"Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia","volume":"31","author":"Lin","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R52-20250314","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R53-20250314","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004714-199408000-00002","article-title":"Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response","volume":"14","author":"Perry","year":"1994","journal-title":"J Clin Psychopharmacol."},{"key":"R54-20250314","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5414\/CPP41003","article-title":"Therapeutic drug monitoring of clozapine and relapse-a retrospective study of routine clinical data","volume":"41","author":"Ulrich","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R55-20250314","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0029-1220890","article-title":"Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey","volume":"42","author":"Waldschmitt","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"R56-20250314","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/00365519309092573","article-title":"Diagnostic accuracy evaluation using ROC curve analysis","volume":"53","author":"Huguet","year":"1993","journal-title":"Scand J Clin Lab Invest"},{"key":"R58-20250314","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R59-20250314","doi-asserted-by":"crossref","first-page":"e0229381","DOI":"10.1371\/journal.pone.0229381","article-title":"Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: a meta-analysis of randomised placebo-controlled trials","volume":"15","author":"Hengartner","year":"2020","journal-title":"PLoS One"},{"key":"R60-20250314","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jad.2012.12.001","article-title":"What does the HAMD mean?","volume":"148","author":"Leucht","year":"2013","journal-title":"J Affect Disord"},{"key":"R61-20250314","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-0327(02)00080-0","article-title":"Relationships among measures of treatment outcome in depressed patients","volume":"76","author":"Mulder","year":"2003","journal-title":"J Affective Disord"},{"key":"R62-20250314","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jclinepi.2020.04.022","article-title":"Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level","volume":"124","author":"Guizzaro","year":"2020","journal-title":"J Clin Epidemiol."},{"key":"R63-20250314","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application","volume":"75","author":"Leucht","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"R64-20250314","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatrica Scand Supplementum"},{"key":"R65-20250314","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr Bull."},{"key":"R66-20250314","doi-asserted-by":"crossref","first-page":"832209","DOI":"10.3389\/fpsyt.2022.832209","article-title":"Molecular imaging of dopamine partial agonists in humans: implications for clinical practice","volume":"13","author":"Hart","year":"2022","journal-title":"Front Psychiatry"},{"key":"R67-20250314","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FTD.0000000000001142","article-title":"Update lessons from positron emission tomography imaging Part I: a systematic critical review on therapeutic plasma concentrations of antipsychotics","volume":"46","author":"Hart","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R68-20250314","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FTD.0000000000001142","article-title":"Update lessons from PET imaging Part II: a systematic critical review on therapeutic plasma concentrations of antidepressants","volume":"46","author":"Hart","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R69-20250314","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-005-0579-5","article-title":"Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review","volume":"255","author":"Adli","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R70-20250314","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","article-title":"Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?","volume":"22","author":"Rasmussen","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R71-20250314","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-011-2319-z","article-title":"\u201cThere is no dose-response relationship in psychopharmacotherapy\u201d vs \u201cpharmacotherapy in psychiatry is based on ligand-receptor interaction\u201d: a unifying hypothesis and the need for plasma concentration based clinical trials","volume":"217","author":"Eggart","year":"2011","journal-title":"Psychopharmacology"},{"key":"R72-20250314","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges","volume":"153","author":"VanderZwaag","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R73-20250314","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JCP.0b013e318218f503","article-title":"Association between citalopram serum levels and clinical improvement of patients with major depression","volume":"31","author":"Ostad Haji","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R74-20250314","first-page":"75","article-title":"Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder","volume":"32","author":"Volavka","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"R76-20250314","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R77-20250314","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eurpsy.2004.09.009","article-title":"Clinical outcome and olanzapine plasma levels in acute schizophrenia","volume":"20","author":"Mauri","year":"2005","journal-title":"Eur Psychiatry"},{"key":"R78-20250314","doi-asserted-by":"crossref","first-page":"e0148539","DOI":"10.1371\/journal.pone.0148539","article-title":"Application of plasma levels of olanzapine and N-Desmethyl-Olanzapine to monitor clinical efficacy in patients with schizophrenia","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"key":"R79-20250314","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0000000000000770","article-title":"A pilot study of the usefulness of a single olanzapine plasma concentration as an indicator of early drug effect in a small sample of first-episode psychosis patients","volume":"37","author":"Zabala","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"R80-20250314","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R82-20250314","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.euroneuro.2017.06.009","article-title":"Escitalopram plasma levels and antidepressant response","volume":"27","author":"Florio","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"R83-20250314","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0269881113512041","article-title":"Genetic differences in cytochrome P450 enzymes and antidepressant treatment response","volume":"28","author":"Hodgson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"R84-20250314","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.euroneuro.2016.02.003","article-title":"Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression-The EMC trial","volume":"26","author":"Tadi\u0107","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"R85-20250314","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pscychresns.2016.03.006","article-title":"Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: a positron emission tomography study with [(11)C]DASB","volume":"251","author":"Arakawa","year":"2016","journal-title":"Psychiatry Res Neuroimaging"},{"key":"R86-20250314","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40262-016-0444-x","article-title":"Regional differences in serotonin transporter occupancy by escitalopram: an [(11)C]DASB PK-pd study","volume":"56","author":"Kim","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R87-20250314","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.neuroimage.2012.07.023","article-title":"Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas","volume":"63","author":"Lanzenberger","year":"2012","journal-title":"Neuroimage"},{"key":"R88-20250314","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0009-9120(82)90511-2","article-title":"Monitoring of tricyclic antidepressant therapy","volume":"15","author":"Dawling","year":"1982","journal-title":"Clin Biochem"},{"key":"R89-20250314","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.1999.00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline","volume":"48","author":"Gupta","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R90-20250314","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R91-20250314","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jagp.2013.01.045","article-title":"Therapeutic window for striatal dopamine D(2\/3) receptor occupancy in older patients with schizophrenia: a pilot PET study","volume":"22","author":"Uchida","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"R92-20250314","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.jcp.0000185427.08268.db","article-title":"Effects of age and sex on olanzapine plasma concentrations","volume":"25","author":"Weiss","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R93-20250314","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0924-977X(02)00051-2","article-title":"Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram","volume":"12","author":"Baumann","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"R94-20250314","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000001092","article-title":"Behind the curtain: therapeutic drug monitoring of psychotropic drugs from a laboratory analytical perspective","volume":"46","author":"Scherf-Clavel","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R95-20250314","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":"Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study","volume":"21","author":"Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R96-20250314","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FTD.0000000000000830","article-title":"Therapeutic drug monitoring of long-acting injectable antipsychotic drugs","volume":"43","author":"Schoretsanitis","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R97-20250314","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17425255.2023.2220962","article-title":"Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations","volume":"19","author":"Schoretsanitis","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:03:02Z","timestamp":1741964582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001264","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"2024-05-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}